Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05108805 · ClinicalTrials.gov registry record · Phase 4
Chimeric Antigen Receptor (CAR) T Cell Therapy With YESCARTA in the Outpatient Setting
A Phase 4 study, sponsored by Vanderbilt-Ingram Cancer Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 25
- Enrollment target
NCT05108805 is a Phase 4 study that has completed, run by Vanderbilt-Ingram Cancer Center. The registered enrollment target is 25 participants.
The verdict
NCT05108805, a Phase 4 study, has completed, sponsored by Vanderbilt-Ingram Cancer Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 25 participants
- Enrollment target
Study Summary
We hope to demonstrate that YESCARTA can be safely administered in the outpatient setting if we closely monitor subjects with physical exams, wearable devices, and telemedicine visits and only admit those who meet specified criteria
Interventions
- BIOLOGICAL Axicabtagene Ciloleucel
- PROCEDURE Telemedicine Visit
- PROCEDURE Vital sign measurements
- PROCEDURE Out-Patient Clinic Visit
- PROCEDURE Blood pressure and pulse oximeter
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2021-12-02 |
| Est. Completion | 2023-12-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05108805
The ClinicalTrials.gov registry entry for NCT05108805 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt-Ingram Cancer Center, which has 189 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Axicabtagene Ciloleucel is the first listed.
NCT05108805 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05108805 about?
NCT05108805 is a clinical study titled "Chimeric Antigen Receptor (CAR) T Cell Therapy With YESCARTA in the Outpatient Setting". We hope to demonstrate that YESCARTA can be safely administered in the outpatient setting if we closely monitor subjects with physical exams, wearable devices, and telemedicine visits and only admit those who meet specified criteria
What is the current status of trial NCT05108805?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 25 participants. The study started on 2021-12-02. Estimated completion is 2023-12-08.
What interventions are being tested in trial NCT05108805?
The interventions under investigation include: Axicabtagene Ciloleucel (BIOLOGICAL), Telemedicine Visit (PROCEDURE), Vital sign measurements (PROCEDURE), Out-Patient Clinic Visit (PROCEDURE), Blood pressure and pulse oximeter (PROCEDURE).
Who is sponsoring clinical trial NCT05108805?
This trial is sponsored by Vanderbilt-Ingram Cancer Center, which has 189 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.